Tagged with Patient access

India With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to the country’s vast population, two pioneering pharmaceutical multinationals – Novartis and Janssen – have stepped up with innovative initiatives to fill the gaps. “Economists such as Michael Porter see Arogya Parivar as a…

Brazil Fraser Hall, country president of AstraZeneca Brazil, describes the current trends and dynamics shaping the Brazilian pharmaceutical market and documents the promising partnership opportunities he envisions to significantly increase patient access in both the private and public sectors. You were appointed country president of AstraZeneca Brazil in September 2016 after…

Brazil Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for Brazilians, and the company’s current research on immunostimulants. Before presenting the company, could you tell our readers what motivated you…

India Dilip G Shah, secretary-general of the Indian Pharmaceutical Alliance (IPA) and member of the Expert Review Committee on Access to Medicine (ATM), discusses the association’s commitment to assisting the Indian government with policies that ensure access to affordable medicines for all as well as the requirements that every candidate needs…

Tunisia Hamouda Zaouia, regional manager Africa, Middle East and Turkey, and Khaled Laouiti, general manager Tunisia, Libya and sub-Saharan Africa, stress the important strategic position the African continent has for Pierre Fabre. They describe the company’s approach when tailoring its portfolio to truly target the needs of patients and Pierre Fabre’s…

Poland Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care and market access in the oncology community. She also highlights the importance of a coordinated approach towards the treatment of…

Brazil Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by this ambitious company and documents Biomm’s vision to develop a balanced portfolio combining very innovative biologicals and leading biosimilars in…

Poland Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims to integrate pharmacoecomonics to ensure Poland can find an efficient balance between innovative and generic treatments for long-term stability. Furthermore,…

Canada Newly appointed minister of health of Canada, The Honourable Ginette Petitpas Taylor, shares the core tenets of her mandate, the Federal government’s priorities for investment into the Canadian healthcare ecosystem, as well as the strategic significance of the life sciences industry for the country. Healthcare was a core issue on…

Tunisia Karim Bendhaou, president of Merck North West Africa, discusses the region-specific strategies he has instigated, how a country like Tunisia would be well advised to focus its resources on e-health rather than production, and highlights the numerous initiatives that Merck has set up to develop healthcare access in Africa. Where…

Tunisia Moez Lidinallah Mokaddem, ENA graduate and CEO of the Central Pharmacy of Tunisia (PCT), introduces the institution he works for and the central role it plays in the import of drugs to the country, as it holds an absolute monopole on said imports. He also provides us with an insight…

Bulgaria Krassimira Chemishanska, country director at Amgen Bulgaria, showcases the role of innovative players in the country, the importance of moving towards a value-based assessment system, and how Amgen has performed since its entrance to the Bulgarian market back in 2009. You opened the Bulgarian affiliate back in 2009. How challenging…